Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action

Journal of Hypertension

Volumn 16, Issue 6, 1998, Pages 793-799

  Cao, Zemin ^a   Hulthén, U Lennart ^a   Allen, Terri J ^a   Cooper, Mark E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin converting enzyme inhibition; Angiotensin II type 1 receptor antagonism; Calcium antagonism; Diabetes; Icatibant; Lacidipine; Mibefradil; Ramipril; Valsartan; Vascular hypertrophy

Indexed keywords

ALPHA ACTIN; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; LACIDIPINE; MIBEFRADIL; RAMIPRIL; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; CALCIUM ANTAGONISM; CONTROLLED STUDY; HYPERTROPHY; MALE; MESENTERIC ARTERY; NONHUMAN; ORAL DRUG ADMINISTRATION; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

EID: 0031863425     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816060-00010     Document Type: Article

References (48)

1. Hsueh WA, Anderson PW. Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. Am J Cardiol 1993; 72:14H-21H.
2. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265:F477-F486.
3. Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 1976; 57:419-434.
4. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62:749-756.
5. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991; 17:626-635.
6. Kato H, Hou J, Chobanian AV, Brecher P. Effect of angiotensin II infusion and inhibition of nitric oxide synthase on the rat aorta. Hypertension 1996; 28:153-158.
7. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994; 43:1221-1228.
8. Rumble JR, Komers R, Cooper ME. Kinins or nitric oxide, or both, are involved in the antitrophic effect of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens 1996; 14:601-607.
9. Vranes D, Cooper ME, Dilley RJ. Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies. J Vasc Res 1995; 32:183-189.
10. Dragovic T, Minshall R, Jackman HL, Wang LX, Erdos EG. Kininase II-type enzymes. Their putative role in muscle energy metabolism. Diabetes 1996; 45 (suppl 1):S34-S37.
11. Komers R, Cooper ME. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins. Am J Physiol 1995; 268:F588-F594.
12. Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994; 45:537-543.
13. Harris RC, Martinez MM: Angiotensin II-mediated renal injury. Miner Electrolyte Metab 1995; 21:328-335.
14. Perico N, Amuchastegui CS, Malanchini B, Bertani T, Remuzzi G. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. Exp Nephrol 1994; 2:220-228.
15. Rumble JR, Doyle AE, Cooper ME. Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes. Am J Hypertens 1995; 8:53-57.
16. Porteri E, Rizzoni D, Castellano M, Bettoni G, Muiesan LM, Salvetti M, et al. Structural changes of small resistance arteries in spontaneously hypertensive rats. J Hypertens 1997; 15:619-625.
17. 2+ channels by Ro 40-5967. Circ Res 1994; 75:144-148.
18. Hulthén LU, Cao Z, Rumble JR, Cooper ME, Johnston CI. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus - effect of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade. Am J Hypertens 1996; 859-901.
19. Allen T, Cao Z, Youssef S, Hulthén UL, Cooper ME. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes 1997; 46:1612-1618.
20. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23:439-449.
21. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE. Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997; 51:1553-1567.
22. Cristofori P, Micheli D, Terron A, Gaviraghi G. Lacidipine: experimental evidence of vasculoprotective properties. J Cardiovasc Pharmacol 1994; 23 (suppl 5):S90-S93.
23. Buñag RD. Validation in awake rat of a tail-cuff method for measurement of systolic blood pressure. J Appl Physiol 1973; 34:279-282.
24. Mendelsohn F, Hutchinson J, Johnston CI: A review of plasma renin measurements and their clinical significance. Aust NZ J Med 1971; 1:86-93.
25. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G. Glomerular filtration rate in the streptozocin diabetic rat: the role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes 1990; 38:1182-1190.
26. Andrews PM, Coffey AK. A technique to reduce fixation artifacts to kidney proximal tubules. Kidney Int 1984; 25:964-968.
27. Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, et al. Vascular hypertrophy in experimental diabetes; role of advanced glycation end products. J Clin Invest 1997; 99:1016-1027.
28. Heagerty AM, Aalkjær C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 1993; 21:391-397.
29. Simonsen U, Ehrnrooth E, Gerdes LU, Faergemann O, Buch J, Andreasen F, et al. Functional properties in vitro of systemic small arteries from rabbits fed a cholesterol-rich diet for 12 weeks. Clin Sci Colch 1991; 80:119-129.
30. Vranes D, Dilley RJ, Cooper ME. Vascular changes in the diabetic kidney: effects of ACE inhibition. J Diabetes Complications 1995; 9:296-300.
31. Castellano M, Rizzoni D, Beschi M, Bohm M, Porteri E, Bettoni G, et al. Chronic ACE-inhibitor treatment and adrenergic mechanisms in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995; 26:381-387.
32. Gohlke P, Linz W, Scholkens BA, Wiemer G, Martorana P, Van EP, et al. Effect of chronic high- and low-dose ACE inhibitor treatment on cardiac and vascular hypertrophy and vascular function in spontaneously hypertensive rats. Exp Nephrol 1994; 2:93.
33. Mulvany MJ. Effects of angiotensin converting enzyme inhibition on vascular remodelling of resistance vessels in hypertensive patients. J Hypertens 1996; 14(suppl 6):S21-S24.
34. Campbell DJ, Kladis A, Duncan AM: Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 1993; 21:155-165.
35. Raij L: Mechanisms of vascular injury: the emerging role of the endothelium. J Am Soc Nephrol 1991; 2:82-88.
36. Hollenberg NK, Fisher ND: Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension 1995; 26:602-609.
37. Linz W, Wiemer G, Scholkens BA. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacot 1993; 22 (suppl 9):S1-S8.
38. Abdelrahman AM, Burrell LM, Johnston CI: Blockade of the renin-angiotensin system at different sites: effect on renin, angiotensin and aldosterone. J Hypertens 1993; 11 (suppl):S23-S26.
39. Villa E, Rábano A, Cazes M, Cloarec A, Ruilope LM, Garcin-Robles R. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997; 10:275-281.
40. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90:456-461.
41. Betocchi S, Chiariello M. Effects of calcium antagonists on left ventricular structure and function. J Hypertens 1993; 11 (suppl):S33-S37.
42. Gaviraghi G, Micheli D, Terron A, Cristofori P. Lacidipine: prevention of vascular damage induced by hypertension. J Cardiovasc Pharmacol 1991; 18 (suppl 11):S7-S12.
43. Cristofori P, Sbarbati A, Accordini C, Terron A, Micheli D. Protective action of lacidipine in cardiac hypertrophy of the spontaneously hypertensive stroke-prone rat: an ultrastructural study. J Submicrosc Cytol Pathol 1994; 26:331-340.
44. 2+] distribution and signalling in vascular hypertrophy. Adv Exp Med Biol 1991; 304:303-314.
45. van Zwieten PA. Vascular effects of calcium antagonists: implications for hypertension and other risk factors for coronary heart disease. Am J Cardiol 1989; 64:1171-1211.
46. Lüscher TF, Clozel J-P, Noll G: Pharmacology of the calcium antagonist mibefradil. J Hypertens 1997; 15 (suppl 3):511-518.
47. Ménard J, Karam H, Véniant M, Heudes D, Bruneval P, Clozel J-P. Effects of calcium blockade on end-organ damage in experimental hypertension. J Hypertens 1997; 15 (suppl 3):S19-S30.
48. Munzenmaier DH, Greene AS. Angiotensin II mediates a sustained rise in nuclear and cytoplasmic calcium via multiple receptor subtypes. Am J Physiol 1995; 269:H565-H570.